CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


The PREPARE programWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 PRomoting Exercise During the Pandemic to Increase Activity and Reduce Effects of Social Isolation for COVID: The PREPARE for COVID Trial

This is a randomized trial of home-based exercises versus control for older adults during the COVID-19 pandemic. The hypothesis is that participation in a home-based program will reduce the risk of adverse effects of physical distancing by decreasing patient-reported disability, improving mental health and avoiding hospitalization or institutionalization for vulnerable older people

NCT04392115 Comorbidities and Coexisting Conditions Social Isolation Behavioral: The PREPARE program

Primary Outcomes

Description: The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) will be used . It is a patient-reported disability scale that assesses limitations in six major life domains - cognition, mobility, self-care, social interaction, life activities and participation in society. Participants will report if they have had no difficulty, mild difficulty, moderate difficulty, severe difficulty or extreme difficulty (simply cannot do) with the items listed.

Measure: Patient-reported disability 90 days after enrollment

Time: Assessing change in score from baseline data collection to 90 days from enrollment

Secondary Outcomes

Description: The Patient Health Questionnaire-9 item (PHQ-9) and the Generalized Anxiety Disorder 7-item (GAD-7) are validated tools for diagnosing anxiety and depression.

Measure: Mental Health

Time: Assessing change in the participants GAD-7 score from baseline to monthly scores for 12 months.

Description: Step count using pedometer

Measure: Function

Time: Monthly step count from enrollment to monthly step counts for 12 months from enrollment.

Description: The EQ-5D-5L is a validated instrument with Canadian valuation statistics and national use, which informs incremental cost per quality-adjusted life year gained.

Measure: Health-related quality of life

Time: Assessing change in the participants EQ-5D-5L score from baseline to monthly scores for 12 months.

Description: The Clinical Frailty Scale (CFS) provides a global assessment of frailty.

Measure: Frailty

Time: Assessing change in the participants CFS score from baseline to monthly scores for 12 months.

Description: All deaths and death dates will be identified via chart review or telephone call.

Measure: All-cause mortality.

Time: From enrollment to 12 months after enrollment.

Measure: Health System - Emergency Department Visits

Time: Monthly for 12 months following enrollment.

Measure: Health System - Re-admission

Time: Monthly for 12 months following enrollment.

Measure: Health System - Transfer to Long-Term Care

Time: Monthly for 12 months following enrollment.

Measure: COVID-19 test results

Time: Monthly for 12 months following enrollment.

Description: Falls, cardiac or respiratory complications and unplanned healthcare encounters will be collected during the exercise treatment period for the exercise group. For the control group, participants will be asked if they experienced any falls since the time of enrollment up until the day before surgery. Unplanned healthcare encounters will also be collected during the time of enrollment to the final day of the exercise intervention for the intervention group through chart review.

Measure: Safety [Adverse Events]

Time: Assessing frequency of, or change in any safety events from enrollment up to 90 days from enrollment between the exercise group and control group.


No related HPO nodes (Using clinical trials)